麻腮风疫苗第二剂接种后麻疹、腮腺炎和风疹抗体持久性模式及下降速率
研究对4-6岁接种第二剂麻腮风疫苗(MMR2)的儿童随访至接种后12年,再分析302名参与者的纵向数据。多数参与者随访期间保持血清阳性(麻疹96%、腮腺炎88%、风疹79%),抗体下降速率因抗原和个体而异,腮腺炎下降快且变异大,未发现预测因素。
要点
- 随访期间血清阳性率:麻疹96%、腮腺炎88%、风疹79%。
- 麻疹抗体在MMR2后1个月几何平均滴度高(3892 mIU/mL),相同基线滴度且MMR2后增幅<2倍者年均下降9.7%。
- 腮腺炎抗体MMR2后1个月几何平均滴度为151,年均下降9.2%,未发现人口学或临床预测因素。
核心结论
- 抗体衰减速率在个体间和三种抗原组间差异很大;腮腺炎下降快且变异高,但未发现预测因素。
- 未来研究应关注腮腺炎抗体滴度衰减及其对社区保护和个人易感性的影响,鉴于近期接种人群中的疫情。
研究设计与样本
- 对4-6岁接种第二剂麻腮风疫苗(MMR2)的儿童随访至接种后12年,再分析纵向数据,采用回归模型评估抗体下降速率并考虑个体间和个体内差异,共302名参与者。
主要发现
- 随访期间多数参与者保持血清阳性:麻疹96%、腮腺炎88%、风疹79%。
- 麻疹抗体下降速率与MMR2应答和基线滴度相关;风疹抗体下降速率与第一剂MMR(MMR1)接种年龄相关;腮腺炎下降速率无人口学或临床因素相关。
- MMR2后1个月麻疹几何平均滴度(GMT)为3892 mIU/mL,在相同基线滴度且MMR2后增幅<2倍者中年均下降9.7%,增幅≥2倍者下降较慢(≤7.4%)。
- MMR2后1个月风疹GMT为149,MMR1在12-15月龄接种者年均下降2.6%,在>15月龄接种者年均下降5.9%。
- MMR2后1个月腮腺炎GMT为151,年均下降9.2%;仅14%的受试者对所有抗原具有相同的持久性趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibodies to measles, mumps, and rubella decline 3% per year on average, and have a high degree of individual variation. Yet, individual variations and differences across antigens are not well understood. To better understand potential implications on individual and population susceptibility, we reanalyzed longitudinal data to identify patterns of seropositivity and persistence. METHODS: Children vaccinated with the second dose of measles, mumps, rubella vaccine (MMR2) at 4-6 years of age were followed up to 12 years post-vaccination. The rates of antibody decline were assessed using regression models, accounting for differences between and within subjects. RESULTS: Most of the 302 participants were seropositive throughout follow-up (96% measles, 88% mumps, 79% rubella). The rate of antibody decline was associated with MMR2 response and baseline titer for measles and age at first dose of MMR (MMR1) for rubella. No demographic or clinical factors were associated with mumps rate of decline. One month post-MMR2, geometric mean titer (GMT) to measles was high (3892 mIU/mL), but declined on average 9.7% per year among those with the same baseline titer and <2-fold increase post-MMR2. Subjects with ≥2-fold experienced a slower decline (≤7.4%). GMT to rubella was 149 one month post-MMR2, declining 2.6% and 5.9% per year among those who received MMR1 at 12-15 months and >15 months, respectively. GMT to mumps one month post-MMR2 was 151, declining 9.2% per year. Only 14% of subjects had the same persistence trends for all antigens. CONCLUSIONS: The rate of antibody decay varied substantially among individuals and the 3 antigen groups. A fast rate of decline coupled with high variation was observed for mumps, yet no predictors were identified. Future research should focus on better understanding waning titers to mumps and its impacts on community protection and individual susceptibility, in light of recent outbreaks in vaccinated populations.
引用
- Seagle EE, Bednarczyk RA, Hill T, et al. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. Vaccine. 2018. PMID: 29317117. doi:10.1016/j.vaccine.2017.12.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。